BAM
VBIV

Belpointe Asset Management’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Belpointe Asset Management’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-60
Closed -$545 – 3569
2023
Q1 		$545 Hold
60
– – ﹤0.01% 3580
2022
Q4 		$704 Buy
+60
New +$1.06K ﹤0.01% 3499

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Belpointe Asset Management's VBIV Position: Q2 2023 in Review

Belpointe Asset Management sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 60 shares — an estimated $545 sold.

Belpointe Asset Management first reported a position in VBIV in Q4 2022 and held it in 2 quarters. The position peaked at $704 in Q4 2022. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

  • Belpointe Asset Management reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 60 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $545.
  • Belpointe Asset Management first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $704 in Q4 2022.
  • 46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.